Capitol Hill Most NIH activities will cease immediately if government shuts down September 29, 2023Vol.49 No.36By Matthew Bin Han Ong
Drugs & Targets FDA clears automated assay to assess tumor progression in neuroendocrine cancer September 29, 2023Vol.49 No.36
Drugs & Targets Mythic Therapeutics receives FDA Fast Track designation for MYTX-011 in NSCLC with cMET overexpression September 29, 2023Vol.49 No.36
Drugs & Targets FDA grants Merck sBLA priority review for Keytruda + chemoradiotherapy in cervical cancer September 22, 2023Vol.49 No.35
Funding Opportunities FDA opens application for Orphan Products Clinical Trials Grant Program September 15, 2023Vol.49 No.34
Drugs & Targets FDA grants accelerated approval to Elrexfio for r/r multiple myeloma September 08, 2023Vol.49 No.33
Drugs & Targets FDA places partial clinical hold for magrolimab studies in AML September 08, 2023Vol.49 No.33
Drugs & Targets FDA expands Reblozyl’s indication to first-line treatment of anemia in lower-risk myelodysplastic syndromes September 08, 2023Vol.49 No.33
Drugs & Targets FDA clears AION’s continuous temperature monitoring device and software platform September 08, 2023Vol.49 No.33
